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Erratum.
BK Yoo, SD Grosse
In the article by Yoo and Grosse, entitled “The Cost Effectiveness of Screening Newborns 
for Congenital Adrenal Hyperplasia” [Public Health Genomics 2009;12:67–72], the cost-
effectiveness results for newborn screening for congenital adrenal hyperplasia (CAH) do not 
accurately reflect the assumptions stated in Table 1 of the article. Mr. Orban Holdgate 
informed Dr. Grosse that the original cost-effectiveness model incorrectly applied the 80% 
reduction in mortality among infants with the salt-wasting (SW) form of CAH with 
screening to just a subset of infants with SW-CAH.
When the deterministic cost-effectiveness model was corrected for that error, the number of 
deaths from SW-CAH in the screening scenario was 3.2 times less and the number of 
averted deaths was 2.22 times greater. Consequently, the incremental cost-effectiveness ratio 
(ICER) reported in the article, USD 292,000 per life-year (LY) saved, was greatly 
overstated. A corrected estimate by Mr. Holdgate of the base-case ICER, assuming all 
assumptions reported in the original article, is USD 128,000 per LY saved, in 2005. All 
ICERs reported in the original Table 2 for the various sensitivity analyses should be 
similarly adjusted downwards. The results for the probabilistic cost-effectiveness analysis 
should be disregarded; Dr. Grosse was not able to replicate that analysis.
In qualitative terms, the original conclusion of Yoo and Grosse is not affected: newborn 
screening for CAH would not be considered cost-effective using a threshold value of USD 
50,000 per LY saved. However, it might be considered cost-effective if a higher threshold 
value were used.
The correct Table 2 reads as follows:
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